FindTrial
Sign In

MEDI0382

DRUG12 trials

Sponsors

MedImmune LLC

Conditions

Diabetes Mellitus, Type IIHealthy SubjectsHealthy VolunteersObesityRenal InsufficiencySafetyType 2 Diabetes MellitusType II Diabetes Mellitus

Phase 1

A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers
CompletedNCT02394314
MedImmune LLCHealthy Volunteers
Start: 2015-02-28End: 2015-08-31Updated: 2015-09-09
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
CompletedNCT02548585
MedImmune LLCType 2 Diabetes Mellitus
Start: 2015-12-09End: 2017-02-24Updated: 2019-04-05
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects
CompletedNCT03235375
MedImmune LLCRenal Insufficiency
Start: 2017-10-27End: 2018-04-24Updated: 2018-05-01
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
CompletedNCT03347968
MedImmune LLCHealthy Volunteers
Start: 2017-11-27End: 2018-04-09Updated: 2018-04-25
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
CompletedNCT03385369
MedImmune LLCHealthy Subjects, Safety
Start: 2018-01-05End: 2018-04-12Updated: 2019-04-16
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants
CompletedNCT03625778
MedImmune LLCObesity
Start: 2018-08-14End: 2019-08-25Updated: 2021-08-23

Phase 2

A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
CompletedNCT03244800
MedImmune LLCType 2 Diabetes Mellitus
Start: 2017-09-04End: 2018-01-23Updated: 2019-11-19
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
CompletedNCT03444584
MedImmune LLCType 2 Diabetes Mellitus
Start: 2018-05-08End: 2018-12-06Updated: 2020-01-13
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated
CompletedNCT03550378
MedImmune LLCRenal Insufficiency, Type II Diabetes Mellitus
Start: 2018-06-29End: 2019-02-04Updated: 2020-04-13
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
CompletedNCT03555994
MedImmune LLCType 2 Diabetes Mellitus
Start: 2018-05-31End: 2021-04-14Updated: 2024-11-12
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus
CompletedNCT03596177
MedImmune LLCDiabetes Mellitus, Type II, Obesity
Start: 2018-09-26End: 2019-12-22Updated: 2023-01-19
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
CompletedNCT03745937
MedImmune LLCType 2 Diabetes Mellitus
Start: 2019-01-07End: 2019-05-28Updated: 2020-06-05

Related Papers

Characterisation of cotadutide's dual GLP‐1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
British Journal of Pharmacology2024-02-259 citations
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes
Nature Metabolism2023-12-0844 citations
Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study.
2023-05-042 citations
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Diabetes Obesity and Metabolism2022-04-1165 citations
674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD
Diabetes2021-06-012 citations
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
The Journal of Clinical Endocrinology & Metabolism2019-10-14115 citations
1030-P: Effect of MEDI0382 on the Pharmacodynamics and Pharmacokinetics of Warfarin or Esmolol in Healthy Volunteers
Diabetes2019-06-01
1027-P: A Phase 1, Open-Label, Single-Dose Study to Evaluate Pharmacokinetics of MEDI0382 in Patients with Renal Impairment
Diabetes2019-06-01
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
2018-06-23213 citations
MEDI0382, a GLP/Glucagon Receptor Dual Agonist, Significantly Reduces Hepatic Fat Content in Subjects with Type 2 Diabetes Mellitus
Diabetes2018-06-228 citations
MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes—A Multiple-Ascending-Dose Study
Diabetes2018-06-22
Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes
Diabetes2018-06-22
Effects of MEDI0382 on Pancreatic and Incretin Hormones
Diabetes2018-06-22